220041-96-3

Basic information

• Product Name: (R)-4-benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one
• Synonyms: (R)-4-benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one
• CAS NO: 220041-96-3
• Molecular Weight: 329.783
• Mol File: 220041-96-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (R)-4-benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one(220041-96-3)
• EPA Substance Registry System: (R)-4-benzyl-3-(2-(4-chlorophenyl)acetyl)oxazolidin-2-one(220041-96-3)

Safety Data

• Hazardous Substances Data: 220041-96-3(Hazardous Substances Data)

Upstream product

• 1878-66-6 4-chlorophenylacetic Acid 
• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 
• 25026-34-0 4-chlorophenacetyl chloride 

Downstream Products

• 1001264-89-6 (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-yiamino)propan-1-one 
• 1396257-04-7 tert-butyl (S)-(3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)(2,4-dimethoxybenzyl)carbamate 
• 1396256-89-5 tert-butyl (S)-(3-((R)-4-benzyl-2-oxooxazolidin-3-yl)-2-(4-chlorophenyl)-3-oxopropyl)isopropylcarbamate 
• 1396256-36-2 C₂₇H₃₆ClN₅O₃ 
• 1396258-35-7 C₂₄H₃₁ClFN₅O 

Relevant articles and documents

AKT INHIBITOR

The present invention discloses an AKT inhibitor, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a preparation method thereof, and the use thereof in prevention and/or treatment of a disease mediated by AKT protein kinase.

Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors

The discovery and optimization of a series of 6,7-dihydro-5H-cyclopenta[d] pyrimidine compounds that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported. The initial design and optimization was guided by the use of X-ray structures of inhibitors in complex with Akt1 and the closely related protein kinase A. The resulting compounds demonstrate potent inhibition of all three Akt isoforms in biochemical assays and poor inhibition of other members of the cAMP-dependent protein kinase/protein kinase G/protein kinase C extended family and block the phosphorylation of multiple downstream targets of Akt in human cancer cell lines. Biological studies with one such compound, 28 (GDC-0068), demonstrate good oral exposure resulting in dose-dependent pharmacodynamic effects on downstream biomarkers and a robust antitumor response in xenograft models in which the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway is activated. 28 is currently being evaluated in human clinical trials for the treatment of cancer.

PYRROLOPYRIDINES AS KINASE INHIBITORS

Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Formula, (I).